Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT00959647
An Open-label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study
Eugene and Gloria Bauer Professor
Clinical Professor, Dermatology
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Professor of Dermatology
This study only enrolled participants who took part in previous studies of vismodegib
conducted by Genentech.
Inclusion Criteria:
- Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study
or continued to receive vismodegib at the time the Genentech-sponsored parent study
closed.
- Expectation by the investigator that the participant may continue to benefit from
additional vismodegib treatment.
Exclusion Criteria:
- Intervening anti-tumor therapy not specified in the parent study (ie,
non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or
photodynamic therapy).
drug: bevacizumab
drug: FOLFIRI
drug: FOLFOX
drug: Vismodegib
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061